SUVENBSESuven Life Sciences LtdMediumNeutral
Announced Fri, 29 May · 15:34 IST

Rectification order for Assesment year 2020-21

Regulatory & Legal View source PDF

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.5%1-day move
₹280.00
prior close
₹297.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.7-5.0-5.1-5.1-1.5-1.5-4.5-15.7-16.8-3.6-5.9-2.2
Up moveDown movePending
AI summary

Suven Life Sciences received a rectification order under Section 154 of the Income Tax Act from the Income Tax Department, Kondapur, Hyderabad. The order disallows weighted deduction claimed under Section 35(2AB) for Research & Development expenditure due to lack of DSIR approval in Form No. 3CL. The company had submitted a detailed reply with legal arguments and merits to contest the notice, but the Assessing Officer proceeded to pass the order anyway. The company is now preferring an appeal to the appellate authority against this rectification order. Management states they do not foresee any material impact on the company's financials, operations, or other activities.

Likely market impact

This is a tax dispute related to R&D deduction claims and does not appear to be material based on company statements. However, it adds to regulatory compliance burden and legal costs as the company pursues an appeal.